
- ONCOLOGY Vol 25 No 11
- Volume 25
- Issue 11
Adoptive T-Cell Immunotherapy: One Step Forward
A recent case report in the New England Journal of Medicine highlights the promising potentials of adoptive T-cell immunotherapy by redirecting them, through chimeric antigen receptors, as a novel and effective therapeutic modality for cancer.
Cell therapy is not a new therapeutic modality anymore. Allogeneic hematopoietic stem cell transplantation is a good example of this treatment strategy, which can successfully overcome chemotherapy-resistant hematological malignancies through graft-vs-leukemia effect.
Adoptive T-cell immunotherapy is another form of cell therapy through transfusing ex vivo expanded T cells. It is an attractive treatment strategy, which uses effector T lymphocytes (CD8+ and CD4+) and regulatory T (Treg) cells, and it has been studied as a therapeutic modality for viral infections and various types of solid and liquid cancers in recent decades.
Despite all the achievements and advances in our understandings of adoptive T-cell therapy, it has not gone beyond early stages of feasibility and safety, and it has been far from real-time clinical application. However, a
Porter and colleagues redirected autologous T cells with chimeric antigen receptor with specificity for B lymphocyte antigen CD19; and they also added costimulatory signaling domains to the chimeric antigen receptor. They used CD137 and CD3-zeta domains. This new strategy is quite attractive since it has the potentials to overcome problems such as short-lived T-cell expansion and transient antitumor effect, which are the major limiting factors for using adoptive T-cell immunotherapy.
Interestingly the patient developed delayed
This case report highlights the promising potentials of adoptive T-cell immunotherapy by redirecting them, through chimeric antigen receptors, as a novel and effective therapeutic modality for cancer.
References:
1. Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011; 36: 725–733.
Articles in this issue
about 14 years ago
Recommendations for Women With Lobular Carcinoma In Situ (LCIS)about 14 years ago
PARP Inhibitors in Breast Cancer: BRCA and Beyondabout 14 years ago
Obesity and Breast Cancerabout 14 years ago
The Obesity and Breast Cancer Connection: Advancing the Agendaabout 14 years ago
PARP Inhibitors: the Story is Still Unfoldingabout 14 years ago
The Challenges of Treating Lobular Carcinoma In Situabout 14 years ago
Lobular Neoplasia: How to Manage With Partial UnderstandingNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.